drugset / Trial / NCT01983735

Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

NCT01983735

Phase 3 Unknown 200 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Timeline

Start
2014-01
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator S-amlodipine Unknown 2.5 mg
Comparator S-amlodipine Unknown 5 mg
Subject Telmisartan Other / unclassified 80 mg

Indications